Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Integrator complex subunit 4 pseudogene 1 (INTS4P1) is classified as a pseudogene in the human genome, meaning it is a genomic fragment similar to the protein-coding gene INTS4 but generally considered nonfunctional and not translated into protein[2][5]. INTS4P1 is also known as INTS4L1 and FLJ25037. Unlike the functional INTS4 gene, which encodes a scaffold protein essential for the Integrator complex's 3′-end processing of snRNAs, the pseudogene INTS4P1 has no confirmed functional role and is not known to participate in molecular pathways, disease, drug interactions, or serve as a therapeutic target[2][5]. Accordingly, it is not relevant to molecular target-based drug discovery or biomarker development. Key clarifications: - INTS4P1 is a **pseudogene**, not a protein or functional target. - Biological function, disease roles, drug interactions, and relevance as a therapeutic target are not established or applicable[2][5]. - INTS4 (not INTS4P1) is the scaffold subunit in the Integrator complex, but INTS4P1 does not encode this protein. Note: If you are looking for the functional subunit, refer to **Integrator complex subunit 4 (INTS4)**, not INTS4P1.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Integrator complex subunit 4 pseudogene 1 (INTS4P1).